Patient characteristics
HER2-positive cancer
ONCOLOGY
Patients were enrolled from September 2016 to June 2020. After enrolling the initial 39 patients treated with original-dose CapeOX (original-dose group), the protocol was revised to incorporate IDMC recommendations, and the subsequent 69 patients were treated with reduced-dose CapeOX (reduced-dose group). The last follow-up analysis was conducted in July 2022. Finally, 108 patients from 26 centers in Japan were enrolled in this study. However, one patient with HER2-positive cancer and three patients with study drug violations—administered generic drugs—were excluded. A total of 104 patients were included in the FAS (Fig. CONSORT diagramPatient characteristicsECOG, Eastern Cooperative Oncology Group